Oneness Biotech Co., Ltd. (TPEX:4743)
Taiwan
· Delayed Price · Currency is TWD 70.00
+1.00 (1.45%)
Apr 2, 2025, 1:30 PM CST
Oneness Biotech Income Statement
Financials in millions TWD. Fiscal year is January - December.
Millions TWD. Fiscal year is Jan - Dec.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2015 - 2019 |
|---|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2015 - 2019 |
| Revenue | 117.93 | 86.78 | 1,066 | 65.77 | 41.61 | Upgrade
|
| Revenue Growth (YoY) | 35.89% | -91.86% | 1520.25% | 58.07% | 208.76% | Upgrade
|
| Cost of Revenue | 54.89 | 54.22 | 221.16 | 20.72 | 10.89 | Upgrade
|
| Gross Profit | 63.03 | 32.56 | 844.39 | 45.04 | 30.72 | Upgrade
|
| Selling, General & Admin | 223.55 | 176.64 | 166.83 | 117.22 | 107.55 | Upgrade
|
| Research & Development | 924.9 | 952.55 | 919.02 | 805.96 | 589.28 | Upgrade
|
| Other Operating Expenses | 0.63 | - | - | - | 7.06 | Upgrade
|
| Operating Expenses | 1,149 | 1,129 | 1,086 | 923.18 | 703.89 | Upgrade
|
| Operating Income | -1,086 | -1,097 | -241.45 | -878.14 | -673.17 | Upgrade
|
| Interest Expense | -9.61 | -5.61 | -4.6 | -4.9 | -5.18 | Upgrade
|
| Interest & Investment Income | 291.83 | 289.39 | 57.51 | 34.75 | 17.64 | Upgrade
|
| Earnings From Equity Investments | -428.9 | -498.78 | 90.02 | 280.31 | 485.93 | Upgrade
|
| Currency Exchange Gain (Loss) | 357.53 | -12.97 | 544.67 | -151.29 | -67.18 | Upgrade
|
| Other Non Operating Income (Expenses) | 6.58 | 7.08 | 8.68 | 12.01 | 4.62 | Upgrade
|
| EBT Excluding Unusual Items | -868.61 | -1,318 | 454.83 | -707.26 | -237.35 | Upgrade
|
| Gain (Loss) on Sale of Investments | 0.11 | -0.03 | -3.2 | 0.97 | -11.77 | Upgrade
|
| Gain (Loss) on Sale of Assets | -0.03 | 0.26 | - | - | - | Upgrade
|
| Asset Writedown | -279.7 | - | - | 6.19 | - | Upgrade
|
| Other Unusual Items | -1.51 | - | - | 304.13 | -0.82 | Upgrade
|
| Pretax Income | -1,150 | -1,317 | 451.63 | -395.96 | -249.94 | Upgrade
|
| Income Tax Expense | 3.29 | 5.29 | 99.73 | 16.86 | 1.74 | Upgrade
|
| Earnings From Continuing Operations | -1,153 | -1,323 | 351.9 | -412.82 | -251.68 | Upgrade
|
| Minority Interest in Earnings | -12.13 | 9.7 | 8.08 | 9.52 | 9.78 | Upgrade
|
| Net Income | -1,165 | -1,313 | 359.98 | -403.3 | -241.9 | Upgrade
|
| Net Income to Common | -1,165 | -1,313 | 359.98 | -403.3 | -241.9 | Upgrade
|
| Shares Outstanding (Basic) | 478 | 474 | 465 | 455 | 426 | Upgrade
|
| Shares Outstanding (Diluted) | 478 | 474 | 472 | 455 | 426 | Upgrade
|
| Shares Change (YoY) | 0.97% | 0.40% | 3.58% | 6.82% | 42.09% | Upgrade
|
| EPS (Basic) | -2.44 | -2.77 | 0.77 | -0.89 | -0.57 | Upgrade
|
| EPS (Diluted) | -2.44 | -2.77 | 0.76 | -0.89 | -0.57 | Upgrade
|
| Free Cash Flow | -395.28 | -512.23 | -968.35 | -384.24 | 113.32 | Upgrade
|
| Free Cash Flow Per Share | -0.83 | -1.08 | -2.05 | -0.84 | 0.27 | Upgrade
|
| Dividend Per Share | - | - | 0.084 | - | - | Upgrade
|
| Gross Margin | 53.45% | 37.52% | 79.25% | 68.49% | 73.83% | Upgrade
|
| Operating Margin | -920.96% | -1263.64% | -22.66% | -1335.27% | -1618.01% | Upgrade
|
| Profit Margin | -988.03% | -1512.82% | 33.78% | -613.25% | -581.42% | Upgrade
|
| Free Cash Flow Margin | -335.20% | -590.25% | -90.88% | -584.26% | 272.37% | Upgrade
|
| EBITDA | -681.01 | -674.23 | 231.23 | -712.66 | -513.47 | Upgrade
|
| EBITDA Margin | - | - | 21.70% | - | - | Upgrade
|
| D&A For EBITDA | 405.04 | 422.4 | 472.68 | 165.48 | 159.7 | Upgrade
|
| EBIT | -1,086 | -1,097 | -241.45 | -878.14 | -673.17 | Upgrade
|
| EBIT Margin | - | - | -22.66% | - | - | Upgrade
|
| Effective Tax Rate | - | - | 22.08% | - | - | Upgrade
|
Source: S&P Global Market Intelligence. Standard template. Financial Sources.